National targeted melanoma screening program is step closer
Read more about 'Skin Checks for Melanoma in Australia Position Statement’, led by MIA in collaboration with expert colleagues across Australia.
MIA’s Co-Medical Directors named 2024 Australians of the Year
We are so proud of our MIA Co-Medical Directors, Prof Georgina Long AO and Prof Richard Scolyer AO, jointly named 2024 Australians of the Year.
Co-Medical Directors named in list of “News Makers of 2023”
Prof Georgina Long and Prof Richard Scolyer have been named in Top 52 News Makers for 2023 by the Sydney Morning Herald 'Good Weekend' magazine.
MIA’s Co-Medical Directors joint NSW 2024 Australian of the Year
Congratulations to MIA Co-Medical Directors, Professor Georgina Long AO and Professor Richard Scolyer AO, jointly named 2024 NSW Australian of the Year.
Prof Richard Scolyer honoured with SMR Lifetime Achievement Award
In recognition of his incredible contribution to melanoma research, Prof Richard Scolyer was presented with the 2023 Lifetime Achievement Award at the Society for Melanoma Research Congress in Philadelphia.
MIA team shines on world stage at SMR
Read more about Melanoma Institute Australia highlights from The Society for Melanoma Research 2023 Congress held in Philadelphia.
Researchers confirm the link between balding and skin cancer
“Research into the genetic drivers of skin cancer is critical” - MIA Co-Medical Directors Prof Georgina Long AO and Prof Richard Scolyer are co-authors on this study into the link between male pattern baldness and skin cancer.
Melanoma science in race against brain cancer – National Press Club
MIA Co-Medical Directors address the National Press Club of Australia detailing world-first breakthroughs in applying melanoma science to Richard Scolyer’s brain cancer.
Cutaneous melanoma: a contemporary overview published in The Lancet
A contemporary overview of Cutaneous melanoma, co-authored by MIA, has been published in The Lancet, one of the world's leading medical journals.
Major advance for neoadjuvant treatment of melanoma
The PBAC recommends expanding current PBS listing for pembrolizumab immunotherapy to allow neoadjuvant (before surgery) treatment of resected stage IIIB-D melanoma.